Cargando…

In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile

From the perspective of psycho-oncology, antipsychotics are widely used for patients with cancer. Although some antipsychotic drugs have anti-tumor effects, these antipsychotic drugs are not applicable for cancer patients because of their severe side effects. Brexpiprazole, a novel serotonin-dopamin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Shuhei, Yamamoto, Masahiro, Togashi, Keita, Sanomachi, Tomomi, Sugai, Asuka, Seino, Shizuka, Yoshioka, Takashi, Kitanaka, Chifumi, Okada, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544401/ https://www.ncbi.nlm.nih.gov/pubmed/31191825 http://dx.doi.org/10.18632/oncotarget.26949

Ejemplares similares

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2019)

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing
por: Suzuki, Shuhei, et al.
Publicado: (2020)

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
por: Sanomachi, Tomomi, et al.
Publicado: (2019)

Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2021)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis
por: Suzuki, Shuhei, et al.
Publicado: (2021)

Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
por: Suzuki, Shuhei, et al.
Publicado: (2018)

Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug
por: Okada, Masashi, et al.
Publicado: (2017)

Inhibition of the Lipid Droplet–Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties
por: Kuramoto, Kenta, et al.
Publicado: (2021)

Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts
por: Okada, Masashi, et al.
Publicado: (2021)

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins
por: Yamamoto, Masahiro, et al.
Publicado: (2022)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo
por: Takeda, Hiroyuki, et al.
Publicado: (2017)

Inhibition of the Phospholipase Cε–c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties
por: Okada, Masashi, et al.
Publicado: (2022)

Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2023)

Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction
por: Kuramoto, Kenta, et al.
Publicado: (2017)

Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
por: Okada, Masashi, et al.
Publicado: (2014)

Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
por: Shibuya, Keita, et al.
Publicado: (2014)

JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
por: Suzuki, Shuhei, et al.
Publicado: (2014)

HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2022)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
por: Mitobe, Yuta, et al.
Publicado: (2023)

The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo
por: Okada, Masashi, et al.
Publicado: (2016)

Targeting JNK for therapeutic depletion of stem-like glioblastoma cells
por: Matsuda, Ken-ichiro, et al.
Publicado: (2012)

ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice
por: Amada, Naoki, et al.
Publicado: (2023)

Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters
por: Hagino, Y, et al.
Publicado: (2011)

Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
por: Amada, Naoki, et al.
Publicado: (2019)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Brexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems
por: Fukuyama, Kouji, et al.
Publicado: (2022)

Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43
por: Fukuyama, Kouji, et al.
Publicado: (2021)

Opposing effects of clozapine and brexpiprazole on β-aminoisobutyric acid: Pathophysiology of antipsychotics-induced weight gain
por: Fukuyama, Kouji, et al.
Publicado: (2023)

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
por: Siwek, Marcin, et al.
Publicado: (2023)

CENTRAL DOPAMINE AND SEROTONIN TURNOVER IN SCHIZOPHRENIA
por: Pandey, R.S., et al.
Publicado: (1987)

The Effect of Obesity on the Availabilities of Dopamine and Serotonin Transporters
por: Nam, Su Bong, et al.
Publicado: (2018)

Dopamine Modulates Serotonin Innervation in the Drosophila Brain
por: Niens, Janna, et al.
Publicado: (2017)

Are dopamine and serotonin involved in COVID-19 pathophysiology?
por: Attademo, L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_odka62o10tv1nevctdng38q05e